

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15 (d) of the
Securities Exchange Act of 1934

September 19, 2006
Date of Report (Date of earliest event reported)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

333-92383
(Commission File Number)

06-1397316
(I.R.S. Employer
Identification No.)

251 Ballardvale Street
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices) (Zip Code)

978-658-6000
(Registrant's Telephone Number, including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02. Results of Operations and Financial Condition

The following information shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.

On September 19, 2006, Charles River Laboratories International, Inc. issued
information on its Web site at <http://ir.criver.com> under "Financial
Reconciliations" that contains financial results for the quarters ended March
26, 2005, June 26, 2005, and September 24, 2005 and for the quarter and fiscal
year ended December 31, 2005, that have been reclassified to reflect the
Company's sale of its Clinical Phase II-IV business and decision to close its
Interventional and Surgical Services business in the second quarter of 2006,
which are now reported as discontinued operations.

ITEM 9.01. Financial Statements and Exhibits

- (a) Not applicable.
- (b) Not applicable.
- (c) Exhibits.

99.1 Financial Results of Charles River Laboratories International,
Inc. for the quarters ended March 26, 2005, June 26, 2005, and
September 24, 2005 and for the quarter and fiscal year ended
December 31, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHARLES RIVER LABORATORIES
INTERNATIONAL, INC.

Dated: September 19, 2006

By: /s/ Joanne P. Acford

Joanne P. Acford, Corporate Senior Vice
President, General Counsel and
Corporate Secretary

Exhibit Index

Exhibit No. -----	Description -----
99.1	Financial Results of Charles River Laboratories International, Inc. for the quarters ended March 26, 2005, June 26, 2005, and September 24, 2005 and for the quarter and fiscal year ended December 31, 2005.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(dollars in thousands, except for per share data)

	Twelve Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- September 24, 2005	Three Months ----- Ended ----- June 25, 2005	Three Months ----- Ended ----- March 26, 2005
Total net sales	\$ 993,328	\$ 258,199	\$ 242,829	\$ 250,890	\$ 241,410
Cost of products sold and services provided	603,624	162,244	146,752	149,286	145,342
Gross margin	389,704	95,955	96,077	101,604	96,068
Selling, general and administrative	157,999	40,485	37,407	41,070	39,037
Amortization of intangibles	47,011	12,428	11,503	11,476	11,604
Operating income (loss)	184,694	43,042	47,167	49,058	45,427
Interest income (expense)	(20,629)	(5,665)	(3,868)	(4,806)	(6,290)
Other, net	(177)	597	(522)	(598)	346
Income before income taxes and minority interests	163,888	37,974	42,777	43,654	39,483
Provision for income taxes	16,261	(18,965)	12,349	12,223	10,654
Income before minority interests	147,627	56,939	30,428	31,431	28,829
Minority interests	(1,838)	(392)	(539)	(422)	(485)
Income from continuing operations	145,789	56,547	29,889	31,009	28,344
Income (loss) from discontinued businesses, net of tax	(3,790)	(6,129)	2,184	851	(696)
Net income (loss)	\$ 141,999	\$ 50,418	\$ 32,073	\$ 31,860	\$ 27,648
Earnings (loss) per common share					
Basic:					
Continuing operations	\$ 2.09	\$ 0.79	\$ 0.42	\$ 0.44	\$ 0.43
Discontinued operations	\$ (0.05)	\$ (0.09)	\$ 0.03	\$ 0.01	\$ (0.01)
Net income	\$ 2.04	\$ 0.70	\$ 0.45	\$ 0.46	\$ 0.42
Diluted:					
Continuing operations	\$ 2.02	\$ 0.77	\$ 0.41	\$ 0.43	\$ 0.41
Discontinued operations	\$ (0.05)	\$ (0.08)	\$ 0.03	\$ 0.01	\$ (0.01)
Net income	\$ 1.96	\$ 0.69	\$ 0.44	\$ 0.44	\$ 0.40
Weighted average number of common shares outstanding					
Basic	69,730,056	71,775,081	71,373,628	69,738,107	65,876,099
Diluted	72,902,385	73,161,997	73,372,960	72,916,234	72,526,888

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)

	Twelve Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- September 24, 2005	Three Months ----- Ended ----- June 25, 2005	Three Months ----- Ended ----- March 26, 2005
Research Models and Services					
Net sales	\$ 503,167	\$ 125,602	\$ 118,882	\$ 130,771	\$ 127,912
Gross margin	215,534	51,254	49,984	57,729	56,567
Gross margin as a % of net sales	42.8%	40.8%	42.0%	44.1%	44.2%
Operating income	159,756	37,685	36,713	43,050	42,308
Operating income as a % of net sales	31.8%	30.0%	30.9%	32.9%	33.1%
Depreciation and amortization	20,015	5,215	5,024	4,903	4,873
Capital expenditures	24,558	7,183	5,583	6,478	5,314
Preclinical Services					
Net sales	\$ 490,161	\$ 132,597	\$ 123,947	\$ 120,119	\$ 113,498
Gross margin	174,170	44,701	46,093	43,875	39,501
Gross margin as a % of net sales	35.5%	33.7%	37.2%	36.5%	34.8%
Operating income	67,918	16,205	19,947	18,596	13,170
Operating income as a % of net sales	13.9%	12.2%	16.1%	15.5%	11.6%
Depreciation and amortization	67,920	17,689	16,510	16,472	17,249
Capital expenditures	69,885	18,087	39,831	5,115	6,852
Unallocated Corporate Overhead	\$ (42,980)	\$ (10,848)	\$ (9,493)	\$ (12,588)	\$ (10,051)

Total

Net sales	\$	993,328	\$	258,199	\$	242,829	\$	250,890	\$	241,410
Gross margin		389,704		95,955		96,077		101,604		96,068
Gross margin as a % of net sales		39.2%		37.2%		39.6%		40.5%		39.8%
Operating income (loss)		184,694		43,042		47,167		49,058		45,427
Operating income as a % of net sales		18.6%		16.7%		19.4%		19.6%		18.8%
Depreciation and amortization		87,935		22,904		21,534		21,375		22,122
Capital expenditures		94,443		25,270		45,414		11,593		12,166

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)

	Twelve Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- September 24, 2005	Three Months ----- Ended ----- June 25, 2005	Three Months ----- Ended ----- March 26, 2005
Research Models and Services					
Net sales	\$ 503,167	\$ 125,602	\$ 118,882	\$ 130,771	\$ 127,912
Operating income	159,756	37,685	36,713	43,050	42,308
Operating income as a % of net sales	31.8%	30.0%	30.9%	32.9%	33.1%
Add back:					
Severance	365	365	-	-	-
	-----	-----	-----	-----	-----
Operating income, excluding specified charges (Non-GAAP)	160,121	38,050	36,713	43,050	42,308
Non-GAAP operating income as a % of net sales	31.8%	30.3%	30.9%	32.9%	33.1%
Preclinical Services					
Net sales	\$ 490,161	\$ 132,597	\$ 123,947	\$ 120,119	\$ 113,498
Operating income	67,918	16,205	19,947	18,596	13,170
Operating income as a % of net sales	13.9%	12.2%	16.1%	15.5%	11.6%
Add back:					
Amortization related to acquisition	43,665	11,599	10,673	10,610	10,783
	-----	-----	-----	-----	-----
Operating income, excluding specified charges (Non-GAAP)	111,583	27,804	30,620	29,206	23,953
Non-GAAP operating income as a % of net sales	22.8%	21.0%	24.7%	24.3%	21.1%
Unallocated Corporate Overhead					
Add back:					
Stock-based compensation related to acquisition	6,369	608	1,085	2,285	2,391
Acceleration of stock options	1,556	1,556	-	-	-
Repatriation	1,305	1,305	-	-	-
	-----	-----	-----	-----	-----
Unallocated corporate overhead, excluding specified charges (Non-GAAP)	(33,750)	(7,379)	(8,408)	(10,303)	(7,660)
Total					
Net sales	\$ 993,328	\$ 258,199	\$ 242,829	\$ 250,890	\$ 241,410
Operating income	184,694	43,042	47,167	49,058	45,427
Operating income as a % of net sales	18.6%	16.7%	19.4%	19.6%	18.8%
Add back:					
Amortization related to acquisition	43,665	11,599	10,673	10,610	10,783
Stock-based compensation related to acquisition	6,369	608	1,085	2,285	2,391
Acceleration of stock options	1,556	1,556	-	-	-
Repatriation	1,305	1,305	-	-	-
Severance	365	365	-	-	-
	-----	-----	-----	-----	-----
Operating income, excluding specified charges (Non-GAAP)	237,954	58,475	58,925	61,953	58,601
Non-GAAP operating income as a % of net sales	24.0%	22.6%	24.3%	24.7%	24.3%

Charles River management believes that non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company's performance. The non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS
(dollars in thousands, except for per share data)

	Twelve Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- December 31, 2005	Three Months ----- Ended ----- September 24, 2005	Three Months ----- Ended ----- June 25, 2005	Three Months ----- Ended ----- March 26, 2005
Net income (loss)	\$ 141,999	\$ 50,418	\$ 32,073	\$ 31,860	\$ 27,648
Less: Discontinued operations	3,790	6,129	(2,184)	(851)	696
Net income from continuing operations	145,789	56,547	29,889	31,009	28,344
Add back:					
Amortization related to acquisition	43,665	11,599	10,673	10,610	10,783
Stock-based compensation related to acquisition	6,369	608	1,085	2,285	2,391
Acceleration of stock options	1,556	1,556			-
Repatriation	1,305	1,305			-
Severance	365	365			-
Deferred financing cost	2,155	2,155			
Deferred tax reversal	(28,271)	(28,271)			
Tax effect	(17,603)	(5,912)	(3,627)	(3,988)	(4,076)
Net income from continuing operations, excluding specified charges (Non-GAAP)	\$ 155,330	\$ 39,952	\$ 38,020	\$ 39,916	\$ 37,442
Calculation of earnings per common share, excluding specified charges (Non-GAAP):					
Net income for purposes of calculating earnings per share, excluding specified charges (Non-GAAP)	\$ 155,330	\$ 39,952	\$ 38,020	\$ 39,916	\$ 37,442
After-tax equivalent interest expense on 3.5% senior convertible debentures	1,208	-	-	295	1,168
Income for purposes of calculating diluted earnings per share, excluding specified charges (Non-GAAP)	\$ 156,538	\$ 39,952	\$ 38,020	\$ 40,211	\$ 38,610
Weighted average shares outstanding - Basic	69,730,056	71,775,081	71,373,628	69,738,107	65,876,099
Effect of dilutive securities:					
3.5% senior convertible debentures	1,462,474	-	-	1,202,939	4,759,455
Stock options and contingently issued restricted stock	1,424,740	1,241,411	1,677,113	1,633,092	1,550,175
Warrants	285,115	145,505	322,219	342,096	341,159
Weighted average shares outstanding - Diluted	72,902,385	73,161,997	73,372,960	72,916,234	72,526,888
Basic earnings (loss) per share	\$ 2.04	\$ 0.70	\$ 0.45	\$ 0.46	\$ 0.42
Diluted earnings (loss) per share	\$ 1.96	\$ 0.69	\$ 0.44	\$ 0.44	\$ 0.40
Basic earnings per share, excluding specified charges (Non-GAAP)	\$ 2.23	\$ 0.56	\$ 0.53	\$ 0.57	\$ 0.57
Diluted earnings per share, excluding specified charges (Non-GAAP)	\$ 2.15	\$ 0.55	\$ 0.52	\$ 0.55	\$ 0.53

Charles River management believes that non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company's performance. The non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.